22nd Century Group, Inc. (NYSE: XXII) has been developing Very Low Nicotine (VLN) cigarettes for a long time and they are getting very close to market. This plant biology company works toward the production of tobacco with low levels of nicotine and hemp/cannabis research.
On March 27, 2019, the Company announced the results of a recently completed, Company-sponsored study involving its VLN cigarettes. The study yielded several statistics that verify the low nicotine level of VLN cigarettes and the positive impact they could have on current smokers.
The Company included this study and its results in its Modified Risk Tobacco Product application submitted to the U.S. Food and Drug Administration for the Company’s VLN cigarettes under the proposed brand name VLN™. The Company’s application seeks the FDA’s authorization to advertise that VLN™ cigarettes contain 95% less nicotine as compared to the 100 top-selling cigarette brands in the United States.
____________________________________
Special Report coming this week: We have been researching 5G and potential opportunities in that sector. We have uncovered a 5G stock that could provide extreme and significant gains for our members this year. This report will be available to view Thursday June 13th, 2019. Text “Traders” to 25827 and be among the first to view this report.
____________________________________
In other news, on April 9, 2019, the Company announced that it had entered into a worldwide strategic research and development agreement with KeyGene NV, a global leader in plant research involving high-value genetic traits and increased crop yields. This exclusive, worldwide collaboration will focus on the development of hemp/cannabis plants with exceptional cannabinoid profiles for medical and therapeutic use, among other applications and other improved agronomic traits for commercial crop applications for agricultural uses.
International Spirits & Beverage Group, Inc. (OTC: ISBG) is a brand incubator in the alcohol/CBD market. They are the authorized importer, licensor, and marketer of premium alcoholic beverage brands, including Besado Tequila, Dziaq, and CBD Infused Products. As a brand incubator the company intends to nurture emerging brands through critical stages of market development, including conceptualization, go-to-market strategy, supply chain and logistics engineering, integrated marketing, and distribution.
Just a week ago the company announced the formation of a strategic partnership with Cannabisfuse.net
, an emerging leader in the affiliate marketing industry for the cannabis, hemp, and CBD products marketplace.
Terry Williams, ISBG CEO stated, “There are two powerful dimensions to this opportunity, and we expect both to meaningfully move the needle in terms of the value proposition for ISBG shareholders. First, we will be a feature brand for all those who flow through the Cannabisfuse.net site for products, services, and news related to cannabis, hemp, and CBD. Second, the deal opens up powerful opportunities in the $6.8 billion affiliate marketing space, granting us access to a number of powerhouse market players.”
The company has further stated it may change its corporate name to reflect a larger presence in the cannabis markets.
Amfil Technologies Inc. (OTC: AMFE) is the operator of 3 businesses:
1). Snakes & Lattes Inc – a board game bar/cafe and board game retailer/distributor/publisher.
2). GRO3 Antimicrobial Systems – Amfil Technologies has a 50% joint venture interest in this ozone based antimicrobial product line targeting the Medical Marijuana cultivation industry.
3). Interloc-Kings Inc. – a hardscape construction company located in southern Ontario.
In April the company discussed that its GRO3 subsidiary has received two purchase orders for its ozone-based antimicrobial technologies from Vessl Inc., the owners of Kalvara, for use in their cannabis-infused beverage production facilities. These purchase orders extend from the Nov 5th, 2018 announcement where GRO3 entered into an exclusive supply agreement with Vessl Inc. and signed an LOI to provide an estimated (8) EcoPrO3 Antimicrobial Systems in 2019.
GRO3 will be supplying EcoPrO3-10SS Ozone Side Stream Systems, which will be integrated into the facilities for the purposes of providing an all-natural sanitization and anti-microbial solution throughout the production process. The EcoPrO3-10SS exclusively utilizes aqueous functionality compared to the EcoPrO3 GRO3 60 system which utilizes an aqueous and gaseous combination. The EcoPrO3-10SS for Kalvara will process all liquids in the formulations prior to their products being prepared and packaged for the end-user.
CV Sciences, Inc. (OTCQB: CVSI) recently participated in the U.S. Food and Drug Administration’s first-ever hearing on cannabis and CBD at the FDA’s headquarters in Silver Spring, MD.
CV Sciences’ Senior Vice President of Science and Regulatory Affairs, Dr. Douglas “Duffy” MacKay, was the only one to submit the formal safety data that the FDA requested. Dr. MacKay’s presentation focused on the importance of identifying and separately regulating different CBD product categories including drugs, foods and dietary supplements.
The Company focuses on developing and commercializing proprietary prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient. CV Sciences initial drug candidate (CVSI-007) is a chewing gum that combines CBD and nicotine, which the Company believes has the potential to effectively treat smokeless tobacco use and addiction.
In April the company’s PlusCBD Oil™ products were used in the first study to date examining the clinical benefit of CBD for the treatment of Post-Traumatic Stress Disorder (PTSD). The study, published in The Journal of Alternative and Complementary Medicine in April 2019, examined the effect of oral CBD administration on symptoms of PTSD in a series of 11 adult patients at an outpatient psychiatry clinic.
From the total sample of 11 patients, 10 experienced a decrease in PTSD symptom severity. The study concluded that administration of oral CBD in addition to routine psychiatric care was associated with PTSD symptom reduction in adults with PTSD.
Special Report coming this week: We have been researching 5G and potential opportunities in that sector. We have uncovered a 5G stock that could provide extreme and significant gains for our members this year. This report will be available to view Thursday June 13th, 2019. Text the word “Traders” to 25827.
Disclosure
Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TNS LLC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. TNS LLC provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS.
TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document.
TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source
